18F-FDG PET/CT, 99mTc-MIBI scintigrafie a MRI při diagnostice pacientů s mnohočetným myelomem a monoklonální gamapatií nejistého významu: srovnání metod

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F08%3A00006077" target="_blank" >RIV/61989592:15110/08:00006077 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

18F-FDG PET/CT, 99mTc-MIBI scintigraphy and MRI in assessment of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of the methods

Popis výsledku v původním jazyce

Introduction: Newer imaging modalities, such as 18F-FDG PET/CT, 99mTc-MIBI scintigraphy and MRI has been recently introduced to assess the activity and extent of disease in patients with multiple myeloma (MM) and gammopathy of unknown significance (MGUS). Aim: To compare the impact of these imaging techniques in evaluation MM and MGUS patients. Material and Methods: Ninety-five consecutive patients with MM and MGUS were enrolled in the study (17 newly diagnosed and 43 relapsed patients with symptomaticMM, 16 patients with asymptomatic MM in stage I without necessity of treatment, and 19 patients with MGUS). Diagnosis and staging were made according to standard criteria. All patients were without chemotherapy or radiotherapy and underwent whole-body 18F-FDG PET/CT, whole-body and SPECT 99mTc-MIBI scintigraphy, and whole-body MRI (only 15 newly diagnosed patients) within a maximum interval of 15 days. The scans were classified as normal (N), diffuse (D)

Název v anglickém jazyce

18F-FDG PET/CT, 99mTc-MIBI scintigraphy and MRI in assessment of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of the methods

Popis výsledku anglicky

Introduction: Newer imaging modalities, such as 18F-FDG PET/CT, 99mTc-MIBI scintigraphy and MRI has been recently introduced to assess the activity and extent of disease in patients with multiple myeloma (MM) and gammopathy of unknown significance (MGUS). Aim: To compare the impact of these imaging techniques in evaluation MM and MGUS patients. Material and Methods: Ninety-five consecutive patients with MM and MGUS were enrolled in the study (17 newly diagnosed and 43 relapsed patients with symptomaticMM, 16 patients with asymptomatic MM in stage I without necessity of treatment, and 19 patients with MGUS). Diagnosis and staging were made according to standard criteria. All patients were without chemotherapy or radiotherapy and underwent whole-body 18F-FDG PET/CT, whole-body and SPECT 99mTc-MIBI scintigraphy, and whole-body MRI (only 15 newly diagnosed patients) within a maximum interval of 15 days. The scans were classified as normal (N), diffuse (D)

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NR9489" target="_blank" >NR9489: Význam 18F-FDG PET/CT, celotělové MR skeletu a 99mTc-MIBI scintigrafie v diagnostice, stážování a monitorování průběhu mnohočetného myelomu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2008

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Nuclear Medicine and Molecular Imaging

ISSN

1619-7070

e-ISSN

—

Svazek periodika

35

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

1

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—